Established industry players actively shape regulatory frameworks and approval pathways that nominally protect public interest but systematically favor incumbent power. Health officials pressure Germany on drug costs, telehealth platforms navigate shifting approval timelines, and biotech companies influence the pace of innovation and market access. Autonomy and competition are constrained not through overt prohibition but through regulatory design that appears neutral while operationally privileging scale and institutional power.